Chronic, recurrent Lymphocytic Leukemia Withdrawn Phase 2 Trials for Idelalisib (DB09054)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02662296Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell TransplantTreatment